Abstract:Acquired tamoxifen (TAM) resistance limits the therapeutic benefit of TAM in patients with hormone-dependent breast cancer. The switch from estrogen-dependent to growth factor-dependent growth is a critical step in this process. However, the molecular mechanisms underlying this switch remain poorly understood. In this study, we established a TAM resistant cell sub line (MCF-7/TAM) from estrogen receptor-α (ER-α66) positive breast cancer MCF-7 cells by culturing ER-α66-positive MCF-7 cells in medium plus 1 μM TAM over 6 months. MCF-7/TAM cells were then found to exhibit accelerated proliferation rate together with enhanced in vitro migratory and invasive ability. And the estrogen receptor-α36 (ER-α36), a novel 36-kDa variant of ER-α66, was dramatically overexpressed in this in vitro model, compared to the parental MCF-7 cells. Meanwhile, the expression of epidermal growth factor receptor (EGFR) in MCF-7/TAM cells was significantly up-regulated both in mRNA level and protein level, and the expression of ER-α66 was greatly down-regulated oppositely. In the subsequent studies, we overexpressed ER-α36 in MCF-7 cells by stable transfection and found that ER-α36 transfected MCF-7 cells (MCF-7/ER-α36) similarly exhibited decreased sensitivity to TAM, accelerated proliferative rate and enhanced in vitro migratory and invasive ability, compared to empty vector transfected MCF-7 cells (MCF-7/V). Real-time qPCR and Western blotting analysis revealed that MCF-7/ER-α36 cells possessed increased EGFR expression but decreased ER-α66 expression both in mRNA level and protein level, compared to MCF-7/V cells. This change in MCF-7/ER-α36 cells could be reversed by neutralizing anti-ER-α36 antibody treatment. Furthermore, knock-down of ER-α36 expression in MCF-7/TAM cells resulted in reduced proliferation rate together with decreased in vitro migratory and invasive ability. Decreased EGFR mRNA and protein expression as well as increased ER-α66 mRNA expression were also observed in MCF-7/TAM cells with down-regulated ER-α36 expression. In addition, blocking EGFR/ERK signaling in MCF-7/ER-α36 cells could restore the expression of ER-α66 partly, suggesting a regulatory function of EGFR/ERK signaling in down-regulation of ER-α66 expression. In conclusion, our results indicated for the first time a regulatory role of ER-α36 in up-regulation of EGFR expression and down-regulation of ER-α66 expression, which could be an underlying mechanism for the growth status switch in breast tumors that contribute to the generation of acquired TAM resistance. And ER-α36 could be considered a potential new therapeutic target in breast tumors which have acquired resistance to TAM.

Relationship of estrogen receptor-beta and its isoform expressions with tamoxifen resistance in human breast cancer

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Advances in mechanism of tamoxifen resistance in estrogen receptor-positive breast cancer

Correlation Between Expressions of Estrogen Receptor, Thymidylate Synthase and CAF Regime Sensibility in Breast Carcinoma

The expressing signification of estrogen receptorβ in breast cancer

Expression and Significance of Estrogen Receptor Isoforms in Different Breast Tissues

Lower Beclin 1 Downregulates HER2 Expression to Enhance Tamoxifen Sensitivity and Predicts a Favorable Outcome for ER Positive Breast Cancer

The Expression of Estrogen Receptor Α, Β in Different Breast Tissues and Its Relation with Breast Cancer

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

[Expression and Significance of Estrogen Receptor Isoforms in the Development of Human Breast Carcinoma].

Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways

Function of Estrogen Receptor Isoforms Α and Β in Endometrial Carcinoma Cells

Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.

Identification of differentially expressed genes in human breast cancer cells induced by 4-hydroxyltamoxifen and elucidation of their pathophysiological relevance and mechanisms

Analysis of Clinico-Pathological Factors Which Influence the Expression of Estrogen Receptor in Breast Carcinoma

Estrogen Receptor Β and Estrogen Receptor Α36 Predict Differential Outcome of Patients with Breast Cancer

A Study on the Expression of Estrogen Receptor and the Effect of Tamoxifen Treatment in Bladder Cancer

Abstract 284: 17Β-Estradiol-induced Expression of Αef1 Confers Tamoxifen Resistance in Breast Cancer

Downregulation of ER-α36 Expression Sensitizes HER2 Overexpressing Breast Cancer Cells to Tamoxifen.

Tamoxifen Enhances Stemness and Promotes Metastasis of ERα36+ Breast Cancer by Upregulating ALDH1A1 in Cancer Cells